Search research articles
Contact Us
Filters
Showing results (181-190 of 217) with videos related to
Page
of 22
Sort By:
Neuro-Oncology
|
March 14, 2020
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma
Vinay K Puduvalli, Jing Wu, Ying Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E Pelloski, Karla V Ballman, Alfred F Furth, et al.
Neuro-Oncology
|
February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Nature Genetics
|
June 22, 2026
Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation
Masashi Nomura, Ramya Raviram, Joshua S Schiffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
It is time to include patients with brain tumors in phase I trials in oncology
Patrick Y Wen, David Schiff, Timothy F Cloughesy, et al.
Neuro-Oncology
|
October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
Vinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
Timothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Journal of Neuro-Oncology
|
October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
Morris D Groves, Vinay K Puduvalli, Susan M Chang, et al.
Neuro-Oncology Advances
|
November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02
Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 217) with videos related to
Sort By:
Page
of 22
Neuro-Oncology
|
March 14, 2020
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma
Vinay K Puduvalli, Jing Wu, Ying Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E Pelloski, Karla V Ballman, Alfred F Furth, et al.
Neuro-Oncology
|
February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Nature Genetics
|
June 22, 2026
Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation
Masashi Nomura, Ramya Raviram, Joshua S Schiffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
It is time to include patients with brain tumors in phase I trials in oncology
Patrick Y Wen, David Schiff, Timothy F Cloughesy, et al.
Neuro-Oncology
|
October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
Vinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
Timothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Journal of Neuro-Oncology
|
October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
Morris D Groves, Vinay K Puduvalli, Susan M Chang, et al.
Neuro-Oncology Advances
|
November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02
Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Page
of 22